# A Phase 2, Study of Ficlatuzumab Plus Erlotinib vs. Placebo Plus Erlotinib in Subjects With Previously Untreated Metastatic, EGFR-mutated NSCLC and BDX004 Positive Label

> **NCT02318368** · PHASE2 · TERMINATED · sponsor: **AVEO Pharmaceuticals, Inc.** · enrollment: 10 (actual)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Ficlatuzumab
- **DRUG:** Erlotinib
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT02318368
- **Lead sponsor:** AVEO Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-11
- **Primary completion:** 2017-01
- **Final completion:** 2017-01
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** Sponsor's decision
- **Last updated:** 2020-10-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02318368

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02318368, "A Phase 2, Study of Ficlatuzumab Plus Erlotinib vs. Placebo Plus Erlotinib in Subjects With Previously Untreated Metastatic, EGFR-mutated NSCLC and BDX004 Positive Label". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02318368. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*